PGxAI continues to lead the charge in pharmacogenetic research with the expansion of its drug database from 700 to 731 drugs, making it the most comprehensive resource available for automated interpretation of PGx data. In addition to this significant expansion, PGxAI has also pioneered a new test for personalizing drug therapy with a range of psychedelics and other psychoactive substances. This groundbreaking test covers substances such as MDMA, Cannabis, LSD, Psilocybin, and more, marking a significant advancement in the realm of personalized therapy for psychoactive substances.
Join us in our mission to redefine healthcare, making it more personalized, effective, and forward-thinking.